CRDF

Company Overview — What Does Cardiff Oncology, Inc. Do?

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Cardiff Oncology, Inc. (CRDF) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Mark Erlander and employs approximately 20 people, headquartered in SAN DIEGO, California. With a market capitalization of $110M, CRDF is one of the notable companies in the Healthcare sector.

Cardiff Oncology, Inc. (CRDF) Stock Rating — Avoid (April 2026)

As of April 2026, Cardiff Oncology, Inc. receives a Avoid rating with a composite score of 26.7/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.CRDF ranks #4,033 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Cardiff Oncology, Inc. ranks #703 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRDF Stock Price and 52-Week Range

Cardiff Oncology, Inc. (CRDF) currently trades at $1.56. The stock lost $0.11 (6.6%) in the most recent trading session. The 52-week high for CRDF is $4.55, which means the stock is currently trading -65.7% from its annual peak. The 52-week low is $1.48, putting the stock 5.4% above its annual trough. Recent trading volume was 698K shares, suggesting relatively thin trading activity.

Is CRDF Overvalued or Undervalued? — Valuation Analysis

Cardiff Oncology, Inc. (CRDF) carries a value factor score of 23/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.19x, versus the sector average of 2.75x. The price-to-sales ratio is 207.09x, compared to 1.66x for the average Healthcare stock.

At current multiples, Cardiff Oncology, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Cardiff Oncology, Inc. Profitability — ROE, Margins, and Quality Score

Cardiff Oncology, Inc. (CRDF) earns a quality factor score of 23/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -103.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -79.2% versus the sector average of -33.1%.

On a margin basis, Cardiff Oncology, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -10755.5% (sector: -66.1%). Net profit margin stands at -10103.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -26.4% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRDF Debt, Balance Sheet, and Financial Health

Cardiff Oncology, Inc. has a debt-to-equity ratio of 31.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 4.20x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $10M.

CRDF has a beta of 1.27, meaning it is more volatile than the broader market — a $10,000 investment in CRDF would be expected to move 27.3% more than the S&P 500 on any given day. The stability factor score for Cardiff Oncology, Inc. is 30/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Cardiff Oncology, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Cardiff Oncology, Inc. reported revenue of $515,000 and earnings per share (EPS) of $-0.17. Net income for the quarter was $-50M. Gross margin was 100.0%. Operating income came in at $-54M.

In Q3 2025, Cardiff Oncology, Inc. reported revenue of $120,000 and earnings per share (EPS) of $-0.17. Net income for the quarter was $-11M. Revenue grew -27.3% year-over-year compared to Q3 2024. Operating income came in at $-12M.

In Q2 2025, Cardiff Oncology, Inc. reported revenue of $121,000 and earnings per share (EPS) of $-0.21. Net income for the quarter was $-14M. Revenue grew -25.8% year-over-year compared to Q2 2024. Operating income came in at $-15M.

In Q1 2025, Cardiff Oncology, Inc. reported revenue of $109,000 and earnings per share (EPS) of $-0.20. Net income for the quarter was $-13M. Revenue grew -46.8% year-over-year compared to Q1 2024. Operating income came in at $-14M.

Over the past 8 quarters, Cardiff Oncology, Inc. has demonstrated a growth trajectory, with revenue expanding from $205,000 to $515,000. Investors analyzing CRDF stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRDF Dividend Yield and Income Analysis

Cardiff Oncology, Inc. (CRDF) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRDF Momentum and Technical Analysis Profile

Cardiff Oncology, Inc. (CRDF) has a momentum factor score of 17/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 38/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

CRDF vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Cardiff Oncology, Inc. (CRDF) ranks #703 out of 838 stocks based on the Blank Capital composite score. This places CRDF in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRDF against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRDF vs S&P 500 (SPY) comparison to assess how Cardiff Oncology, Inc. stacks up against the broader market across all factor dimensions.

CRDF Next Earnings Date

No upcoming earnings date has been announced for Cardiff Oncology, Inc. (CRDF) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRDF? — Investment Thesis Summary

The quantitative profile for Cardiff Oncology, Inc. suggests caution. The quality score of 23/100 flags below-average profitability. The value score of 23/100 indicates premium valuation. Momentum is weak at 17/100, a headwind for near-term performance. High volatility (stability score 30/100) increases portfolio risk.

In summary, Cardiff Oncology, Inc. (CRDF) earns a Avoid rating with a composite score of 26.7/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRDF stock.

Related Resources for CRDF Investors

Explore more research and tools: CRDF vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRDF head-to-head with peers: CRDF vs AZN, CRDF vs SLGL, CRDF vs VMD.